Michael is a senior drug development professional with more than 20 years’ experience in the life sciences industry. He has served in senior leadership positions across disciplines including clinical and preclinical drug development, project & portfolio management, regulatory affairs and metabolism research in both, large international corporations as well as biotech companies.
“Cellestia has delivered a breakthrough in cancer research and therapy in demonstrating the ability to develop highly potent and selective inhibitors of gene transcription factor proteins. The most advanced product is showing strong disease control and now advanced to Phase 2.”
Under his leadership, several new oncology drugs were brought into clinical development and reached clinical proof of concept. Michael holds a PhD in Biotechnology and an MSc in Chemistry.